On the Two-Step Hybrid Design for Augmenting Randomized Trials Using Real-World Data.

IF 1.3 4区 医学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY
Jiapeng Xu, Ruben P A van Eijk, Alicia Ellis, Tianyu Pan, Lorene M Nelson, Kit C B Roes, Marc van Dijk, Maria Sarno, Leonard H van den Berg, Lu Tian, Ying Lu
{"title":"On the Two-Step Hybrid Design for Augmenting Randomized Trials Using Real-World Data.","authors":"Jiapeng Xu, Ruben P A van Eijk, Alicia Ellis, Tianyu Pan, Lorene M Nelson, Kit C B Roes, Marc van Dijk, Maria Sarno, Leonard H van den Berg, Lu Tian, Ying Lu","doi":"10.1080/19466315.2025.2547855","DOIUrl":null,"url":null,"abstract":"<p><p>Hybrid clinical trials, which borrow real-world data (RWD) from patient registries, claims databases, or electronic health records (EHRs) to augment randomized clinical trials, are of increasing interest. Hybrid clinical trials are especially relevant for rare diseases, where the recruitment of large sample sizes may be challenging. While these trials may better use available information, they assume that the RWD and randomized control arm are exchangeable. Violating this assumption can induce bias, inflate Type I error, or adversely affect statistical power. A two-step hybrid design first tests the exchangeability between randomized control arm and external data sources before incorporating RWD as a comparator for statistical inferences (Yuan et al. 2019). This approach reduces the chance of inappropriate borrowing but may simultaneously inflate the Type I error rate. We propose four different methods to control the Type I error rate under the exchangeability assumption. Approach 1 estimates the variance of the overall test statistic and rejects the null hypothesis based on a Z-test. Approach 2 uses a numerical method to determine the exact critical value for Type I error control. Approach 3 splits the Type I error rates according to the equivalence test outcome. Approach 4 adjusts the critical value only when equivalence is established. We illustrate these methods using a hypothetical scenario in the context of amyotrophic lateral sclerosis (ALS). We evaluate the Type I error and power under various clinical trial conditions in comparison with the Bayesian power prior approach (Ibrahim et al. 2015). We demonstrate that our proposed methods and Bayesian power prior control Type I error and increase power under the exchangeability assumption, whereas the method proposed by Yuan et al. (2019) results in an increased Type I error. In the scenario where the exchangeability assumption does not hold, all methods fail to control the Type I error. Our proposed methods, however, limit a maximum Type I error inflation ranging from 6% to 8%, which compares favorably to 10% for Yuan et al. (2019) and 16% for the Bayesian power prior. All methods increase statistical power under the exchangeability condition but may lead to a loss of statistical power when the exchangeability assumption is violated.</p>","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19466315.2025.2547855","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hybrid clinical trials, which borrow real-world data (RWD) from patient registries, claims databases, or electronic health records (EHRs) to augment randomized clinical trials, are of increasing interest. Hybrid clinical trials are especially relevant for rare diseases, where the recruitment of large sample sizes may be challenging. While these trials may better use available information, they assume that the RWD and randomized control arm are exchangeable. Violating this assumption can induce bias, inflate Type I error, or adversely affect statistical power. A two-step hybrid design first tests the exchangeability between randomized control arm and external data sources before incorporating RWD as a comparator for statistical inferences (Yuan et al. 2019). This approach reduces the chance of inappropriate borrowing but may simultaneously inflate the Type I error rate. We propose four different methods to control the Type I error rate under the exchangeability assumption. Approach 1 estimates the variance of the overall test statistic and rejects the null hypothesis based on a Z-test. Approach 2 uses a numerical method to determine the exact critical value for Type I error control. Approach 3 splits the Type I error rates according to the equivalence test outcome. Approach 4 adjusts the critical value only when equivalence is established. We illustrate these methods using a hypothetical scenario in the context of amyotrophic lateral sclerosis (ALS). We evaluate the Type I error and power under various clinical trial conditions in comparison with the Bayesian power prior approach (Ibrahim et al. 2015). We demonstrate that our proposed methods and Bayesian power prior control Type I error and increase power under the exchangeability assumption, whereas the method proposed by Yuan et al. (2019) results in an increased Type I error. In the scenario where the exchangeability assumption does not hold, all methods fail to control the Type I error. Our proposed methods, however, limit a maximum Type I error inflation ranging from 6% to 8%, which compares favorably to 10% for Yuan et al. (2019) and 16% for the Bayesian power prior. All methods increase statistical power under the exchangeability condition but may lead to a loss of statistical power when the exchangeability assumption is violated.

基于真实世界数据的扩大随机试验的两步混合设计
混合临床试验越来越受到人们的关注,混合临床试验从患者登记、索赔数据库或电子健康记录(EHRs)中借用真实数据(RWD)来增强随机临床试验。混合临床试验尤其适用于罕见病,在罕见病中招募大样本量可能具有挑战性。虽然这些试验可能更好地利用现有信息,但它们假设RWD和随机对照组是可互换的。违反这一假设可能导致偏差,扩大I型误差,或对统计能力产生不利影响。两步混合设计首先测试随机对照臂和外部数据源之间的互换性,然后将RWD作为统计推断的比较指标(Yuan et al. 2019)。这种方法减少了不适当借贷的机会,但可能同时增加第一类错误率。在互换性假设下,我们提出了四种不同的方法来控制第一类错误率。方法1估计总体检验统计量的方差,并根据z检验拒绝原假设。方法2使用数值方法来确定第一类误差控制的确切临界值。方法3根据等效性测试结果拆分第一类错误率。方法4仅在建立等效性时才调整临界值。我们在肌萎缩性侧索硬化症(ALS)的背景下用一个假设的场景来说明这些方法。与贝叶斯功率先验方法相比,我们评估了各种临床试验条件下的I型误差和功率(Ibrahim et al. 2015)。我们证明,在互换性假设下,我们提出的方法和贝叶斯功率先验控制I型误差并增加功率,而Yuan等人(2019)提出的方法导致I型误差增加。在互换性假设不成立的场景中,所有方法都无法控制第一类错误。然而,我们提出的方法将最大I型误差膨胀限制在6%至8%之间,相比之下,Yuan等人(2019)的误差为10%,贝叶斯幂先验的误差为16%。所有方法在可互换性条件下都增加了统计能力,但在违反可互换性假设时可能导致统计能力的丧失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
CiteScore
3.90
自引率
16.70%
发文量
56
期刊介绍: Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信